Sanofi

Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

Friday, November 30, 2012 10:55 AM

Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

More... »

Sanofi, T1D Exchange to investigate optimal care for young people with diabetes

Friday, November 16, 2012 02:06 PM

Sanofi, a global healthcare comapny, and T1D Exchange, a non-profit organization focused on type 1 diabetes, will collaborate on the TEENs registry study, which aims to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes, and to deliver recommendations for better disease management and patients outcomes.

More... »

CEO of Sanofi designated as new president elect of EFPIA

Wednesday, November 7, 2012 01:55 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the pharmaceutical industry operating in Europe, has designated Christopher A. Viehbacher, CEO of Sanofi, as the new president elect of EFPIA. He will take up the position as of June 2013 for a two year term.

More... »

Theratechnologies revises business plan, cuts 15 employees

Wednesday, October 31, 2012 10:39 AM

Theratechnologies, a Canadian specialty pharmaceutical company focused on therapeutic peptide products, has revised its business plan which will focus on revenue growth from tesamorelin in the short term and expenditure control.

More... »

Sanofi, Mass. General Hospital launch oncology research collaboration

Thursday, October 11, 2012 07:00 AM

Global healthcare company Sanofi has formed a two-year agreement with Massachusetts General Hospital (MGH) aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors.

More... »

BMS, Sanofi restructure alliance agreement

Thursday, October 4, 2012 10:36 AM

Global biopharmaceutical company Bristol-Myers Squibb and global healthcare company Sanofi have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

More... »

Sanofi to acquire Genfar

Thursday, October 4, 2012 10:04 AM

Global healthcare company Sanofi has signed an agreement to acquire Genfar, a pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will expand its portfolio of affordable pharmaceuticals in Latin America.

More... »

Sanofi selects Bioclinca’s Onpoint as enterprise CTMS

Monday, October 1, 2012 02:15 PM

Pharmaceutical company Sanofi has selected global provider of clinical trial management services BioClinica’s OnPoint as the company’s standard clinical trial management system (CTMS). With this decision, Sanofi plans to utilize OnPoint CTMS for all clinical trial management activity.

More... »

FDA approves new treatment for advanced colorectal cancer

Friday, September 28, 2012 12:19 PM

The FDA has approved Bayer’s and Onyx Pharmaceuticals’ Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body.

More... »